• Home
  •  / CytomX Therapeutics

CytomX Therapeutics

  • Revenue$100.4 MFY, 2020
  • Market Capitalization$124 M2022-06-24

OverviewSuggest Edit

CytomX is unlocking the potential of antibody therapeutics in oncology by developing a novel therapeutic antibody class of highly targeted Probody therapeutics. The Company's Probody Platform allows to design drugs that selectively activate in the tumor microenvironment while reducing drug activity in healthy tissue and in circulation. This ability to localize therapeutic effects to the tumor reduces systemic toxicity, with potential for safer and more effective therapies for a broad array of validated and previously inaccessible oncology targets. Driven by a vision to transform patient lives, CytomX is an advancing multiple Probody cancer immunotherapies and Probody drug conjugates toward clinical investigation, while also applying its technology to bispecific T-cell engaging antibodies and ProCAR-NK cell therapies.
TypePublic
Founded2008
HQSouth San Francisco, CA, USMap
Websitecytomx.com
Employee Ratings3.5
View Jobs (8)

Recent NewsAll News

Latest Updates

Employees (est.) (Dec 2019)158(+16%)
Job Openings8
Revenue (FY, 2020)$100.4 M(+75%)
Share Price (Jun 2022)$1.9(+2%)
Cybersecurity ratingBMore
Discover new suppliers and conduct deeper comparison analysis with Craft for EnterpriseLearn more
Banner background

Key People/Management at CytomX Therapeutics

Sean A. McCarthy

Sean A. McCarthy

President, Chief Executive Officer and Chairman
Amy C. Peterson

Amy C. Peterson

EVP, Chief Development Officer
Carlos Campoy

Carlos Campoy

SVP, Chief Financial Officer
Alison Joly

Alison Joly

SVP, Program and Alliance Management
Jeff Landau

Jeff Landau

SVP, Head of Strategy and Chief Business Officer
Danielle Olander

Danielle Olander

SVP, Talent and Systems Development
Show more

CytomX Therapeutics Office Locations

CytomX Therapeutics has an office in South San Francisco
South San Francisco, CA, US (HQ)
151 Oyster Point Blvd #400
Show all (1)

CytomX Therapeutics Financials and Metrics

CytomX Therapeutics Revenue

CytomX Therapeutics's revenue was reported to be $100.36 m in FY, 2020
USD

Revenue (Q1, 2021)

16.0m

Net income (Q1, 2021)

(15.6m)

EBIT (Q1, 2021)

(15.6m)

Market capitalization (24-Jun-2022)

124.0m

Closing stock price (24-Jun-2022)

1.9

Cash (31-Mar-2021)

329.7m

EV

(181.6m)
CytomX Therapeutics's current market capitalization is $124 m.
Annual
USDFY, 2015FY, 2016FY, 2017FY, 2018FY, 2019FY, 2020

Revenue

7.7m15.0m71.6m59.5m57.5m100.4m

Revenue growth, %

95%

General and administrative expense

12.6m19.9m25.6m33.5m36.8m36.0m

R&D expense

28.4m54.8m92.3m103.9m131.6m112.9m
Quarterly
USDQ3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020Q3, 2020Q1, 2021

Revenue

1.9m2.2m3.1m3.5m11.7m8.8m24.1m14.2m21.3m12.5m29.5m9.0m10.7m49.6m16.6m17.8m16.0m

General and administrative expense

4.1m5.0m4.6m5.0m5.7m6.0m6.2m7.4m9.0m8.1m9.7m9.4m8.5m9.6m8.7m8.6m9.2m

R&D expense

9.2m13.4m12.7m13.3m14.6m28.1m28.9m22.5m25.6m27.5m36.4m30.8m28.0m42.8m24.1m24.0m22.4m

Operating expense total

13.2m18.4m17.4m18.4m20.3m34.1m35.2m29.8m34.6m35.7m46.1m40.2m36.4m52.4m32.7m32.7m31.6m
show all
Annual
USDFY, 2015FY, 2016FY, 2017FY, 2018FY, 2019FY, 2020

Cash

59.8m104.6m177.5m247.6m188.4m191.9m

Accounts Receivable

744.0k2.2m10.1m97.0k13.0k798.0k

Prepaid Expenses

4.4m9.3m7.2m7.1m

Inventories

2.3m3.9m
Quarterly
USDQ3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020Q3, 2020Q1, 2021

Cash

36.2m67.9m62.4m59.8m85.7m272.9m284.2m142.2m132.9m259.8m190.4m149.4m164.6m143.3m291.4m176.8m329.7m

Accounts Receivable

406.0k316.0k285.0k240.0k213.0k158.0k40.2m81.0k25.1m56.0k44.0k10.0m7.0k130.0m206.0k543.0k756.0k

Prepaid Expenses

878.0k3.4m3.4m4.4m4.1m4.6m4.8m5.5m6.4m7.9m8.4m7.5m9.1m9.1m6.9m5.6m5.5m

Current Assets

115.1m184.5m199.6m183.3m166.9m340.7m376.4m367.0m366.7m472.5m405.1m366.7m334.8m400.1m366.6m340.3m400.0m
show all
Annual
USDFY, 2015FY, 2016FY, 2017FY, 2018FY, 2019FY, 2020

Net Income

(35.4m)(58.9m)(43.1m)(84.6m)(102.2m)(32.9m)

Depreciation and Amortization

1.2m1.7m1.6m1.9m146.0k146.0k

Accounts Payable

2.9m1.8m(2.4m)261.0k(374.0k)(857.0k)

Cash From Operating Activities

(27.4m)(2.0m)170.4m(75.5m)(140.5m)5.3m
Quarterly
USDQ3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020Q3, 2020Q1, 2021

Net Income

(23.9m)(16.0m)(30.2m)(44.9m)(8.3m)(33.5m)(43.7m)(15.5m)(28.9m)(52.4m)(14.1m)(43.1m)(66.8m)12.2m(3.5m)(18.2m)(15.6m)

Depreciation and Amortization

877.0k355.0k800.0k1.2m395.0k764.0k1.2m412.0k875.0k1.4m653.0k1.3m109.0k36.0k72.0k109.0k36.0k

Accounts Payable

749.0k246.0k(3.2m)(4.1m)(2.8m)79.0k(3.5m)1.1m(429.0k)2.8m5.2m3.0k152.0k52.0k579.0k(270.0k)(292.0k)

Cash From Operating Activities

(19.2m)(5.5m)10.2m(4.0m)(19.1m)154.1m148.4m(14.6m)(41.2m)(46.8m)(39.0m)(87.7m)(111.0m)(49.7m)47.4m22.7m(29.9m)
show all
USDQ3, 2015

Financial Leverage

-1.2 x
Show all financial metrics

CytomX Therapeutics Operating Metrics

FY, 2016

Patents (Foreign)

4

Patents (US)

13

Patents Pending

144

Phase I Trials Products

1

CytomX Therapeutics Cybersecurity Score

Cybersecurity ratingPremium dataset

B

86/100

Learn more about our premium products
SecurityScorecard logo

CytomX Therapeutics Environment, Social & Governance (ESG) Ratings

CSRHub ESG ratingPremium dataset

40-49

out of 100

Learn more about our premium products
CSRHub logo

CytomX Therapeutics Online and Social Media Presence

CytomX Therapeutics's Trends

Embed Graph

CytomX Therapeutics News and Updates

June 24, 2022

Thinking about buying stock in Toughbuilt Industries, CytomX Therapeutics, Can Fite Biopharma, Hoth Therapeutics, or Bally's?

NEW YORK, June 24, 2022 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for TBLT, CTMX, CANF, HOTH, and BALY. To see how InvestorsObserver's proprietary scoring system rates these stocks, view the InvestorsObserver's PriceWatch Alert by selecting the corresponding link....
May 26, 2022

CytomX Therapeutics Announces First Patient Dosed with CX-904 in Phase 1 Study in Patients with Advanced Solid Tumors

- EGFRxCD3-targeting bispecific is sixth CytomX Probody® therapeutic candidate to enter the clinic - - EGFRxCD3-targeting bispecific is sixth CytomX Probody® therapeutic candidate to enter the clinic -
April 28, 2022

CytomX Therapeutics to Report First Quarter 2022 Financial Results on May 5, 2022

SOUTH SAN FRANCISCO, Calif., April 28, 2022 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of conditionally activated oncology therapeutics, today announced that it will report first quarter 2022 financial results on Thursday, May 5, 2022, after the close of U.…
April 14, 2022

CytomX Therapeutics Announces Retirement of John A. Scarlett, M.D. from Board of Directors

SOUTH SAN FRANCISCO, Calif., April 14, 2022 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of conditionally activated oncology therapeutics, today announced that John A. Scarlett, M.D. is retiring from its board of directors, effective when his current term exp…
March 23, 2022

CytomX Therapeutics Announces Retirement of Frederick W. Gluck from Board of Directors

SOUTH SAN FRANCISCO, Calif., March 23, 2022 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of conditionally activated oncology therapeutics, today announced that Frederick W. Gluck is retiring from its board of directors, effective June 30th, 2022.
March 17, 2022

CytomX Therapeutics to Present Updated Preclinical Data for Conditionally Activated Cytokine Program at AACR Annual Meeting 2022

SOUTH SAN FRANCISCO, Calif., March 17, 2022 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of conditionally activated oncology therapeutics, today announced that preclinical data supporting the ongoing development of its conditionally activated cytokine program…
Show more

CytomX Therapeutics Blogs

June 01, 2022

CytomX Therapeutics to Present at Jefferies 2022 Global Healthcare Conference

SOUTH SAN FRANCISCO, Calif. , June 01, 2022 (GLOBE NEWSWIRE) -- CytomX Therapeutics , Inc. (Nasdaq: CTMX), a leader in the field of conditionally activated oncology therapeutics, today announced that Sean McCarthy, D.Phil., chief executive officer and chairman, will present at the Jefferies
May 05, 2022

CytomX Therapeutics Reports First Quarter 2022 Financial Results and Provides Business Update

CytomX Therapeutics Reports First Quarter 2022 Financial Results and Provides Business Update Content Import Thu, 05/05/2022 - 16:15 CytomX Therapeutics Reports First Quarter 2022 Financial Results and Provides Business Update May 5, 2022 at 4:15 PM EDT Earnin…
April 12, 2022

Probody-Interferon-alpha 2b Combines Antitumor Activity with Improved Tolerability

Alexey Berezhnoy, Ph.D., Presented at the American Association for Cancer Research (AACR) Annual Meeting 2022, April 11th, 2022.
March 03, 2022

Praluzatamab Ravtansine, a CD166-Targeting Antibody– Drug Conjugate, in Patients with Advanced Solid Tumors: An Open-Label Phase I/II Trial

Boni V, Fidler MJ, Arkenau HT, et al. Praluzatamab ravtansine, a CD166-targeting antibody-drug conjugate, in patients with advanced solid tumors: an open-label phase 1/2 trial [published online ahead of print, 2022 Feb 14]. Clin Cancer Res. 2022;clincanres.3656.2021. doi:10.1158/1078-0432.CCR-21-365…
February 28, 2022

CytomX Therapeutics to Present at Cowen 42nd Annual Healthcare Conference

SOUTH SAN FRANCISCO, Calif. , Feb. 28, 2022 (GLOBE NEWSWIRE) -- CytomX Therapeutics , Inc. (Nasdaq: CTMX), a leader in the field of conditionally activated oncology therapeutics, today announced that Sean McCarthy , D.Phil ., chief executive officer and chairman, will participate in a virtual panel
November 18, 2021

Conditional Cytokine Therapeutics for Tumor-Selective Biological Activity: Preclinical characterization of a dual-masked IFN-a2b

Alexey Berezhnoy, Ph.D., Presented at the Society for Immunotherapy of Cancer’s 36th Annual Meeting (SITC 2021), November 13th, 2021.
Show more

 CytomX Therapeutics Frequently Asked Questions

  • When was CytomX Therapeutics founded?

    CytomX Therapeutics was founded in 2008.

  • Who are CytomX Therapeutics key executives?

    CytomX Therapeutics's key executives are Sean A. McCarthy, Amy C. Peterson and Carlos Campoy.

  • How many employees does CytomX Therapeutics have?

    CytomX Therapeutics has 158 employees.

  • What is CytomX Therapeutics revenue?

    Latest CytomX Therapeutics annual revenue is $100.4 m.

  • What is CytomX Therapeutics revenue per employee?

    Latest CytomX Therapeutics revenue per employee is $635.2 k.

  • Who are CytomX Therapeutics competitors?

    Competitors of CytomX Therapeutics include Stingray Therapeutics, Forbius and SQZ Biotech.

  • Where is CytomX Therapeutics headquarters?

    CytomX Therapeutics headquarters is located at 151 Oyster Point Blvd #400, South San Francisco.

  • Where are CytomX Therapeutics offices?

    CytomX Therapeutics has an office in South San Francisco.

  • How many offices does CytomX Therapeutics have?

    CytomX Therapeutics has 1 office.